Adherence to Dihydroartemisinin + Piperaquine Treatment Regimen in Low and High Endemic Areas in Indonesia
- PMID: 35309871
- PMCID: PMC8933069
- DOI: 10.1155/2022/4317522
Adherence to Dihydroartemisinin + Piperaquine Treatment Regimen in Low and High Endemic Areas in Indonesia
Abstract
After decades of successful artemisinin regimen in combating malaria, its effectiveness has decreased since parasite resistance to the treatment regimen has begun to appear. Adherence to artemisinin combination therapy (ACT) in a population is considered to be the key factor contributing to such resistance phenomenon. Although several studies have tried to demonstrate adherence to several ACT types in a population, only a limited number of studies demonstrated adherence to dihyrdroartemisinin + piperaquine (DHP) regimen. The present study was conducted in two localities representing low and high endemic areas in Indonesia. Active case detection (ACD) and passive case detection (PCD) have been applied to screen for malaria case in the localities. At day 3, patients were visited in the house to be interviewed using structured questionnaire. Capillary sample of each patient was also collected on Whatman® filter paper at day 60 to observe the piperaquine metabolite of the patients. 47 and 91 (out of 62 and 138) patients from Jambi and Sumba, respectively, were successfully enrolled in this study. In Jambi, the level of adherence was 66%, while that in Sumba was 79.1%. The associated factors of adherence in our study settings are patient age group (OR = 1.65 [CI: 0.73-3.73]) and patients' knowledge of malaria prevention measure (OR = 0.29 [CI: 0.09-0.9]). Our study suggested that the adherence to ACT medication among population in our study setting is considered to be less than 80%, which needs to be elevated to avoid the growing trend of treatment failure as seen globally. Additionally, our study found that metabolite at day 60 after prescription of piperaquine could be a potential marker for monitoring adherence to piperaquine drug in a population.
Copyright © 2022 Irfanul Chakim et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures
Similar articles
-
Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.Lancet Infect Dis. 2015 Jun;15(6):683-91. doi: 10.1016/S1473-3099(15)70049-6. Epub 2015 Apr 12. Lancet Infect Dis. 2015. PMID: 25877962
-
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.Lancet Glob Health. 2023 Aug;11(8):e1277-e1289. doi: 10.1016/S2214-109X(23)00204-8. Lancet Glob Health. 2023. PMID: 37474234 Clinical Trial.
-
The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.Malar J. 2012 Jun 28;11:217. doi: 10.1186/1475-2875-11-217. Malar J. 2012. PMID: 22741618 Free PMC article. Clinical Trial.
-
Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium vivax malaria in endemic countries: meta-analysis of randomized controlled studies.PLoS One. 2013 Dec 3;8(12):e78819. doi: 10.1371/journal.pone.0078819. eCollection 2013. PLoS One. 2013. PMID: 24312446 Free PMC article. Review.
-
Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis.Lancet Infect Dis. 2018 Aug;18(8):913-923. doi: 10.1016/S1473-3099(18)30297-4. Epub 2018 Jun 18. Lancet Infect Dis. 2018. PMID: 29887371 Free PMC article.
References
-
- WHO. Report of a WHO Technical Consultation . Geneva, Switzerland: World Health Organization; 2001. Antimalarial drug combination therapy.
LinkOut - more resources
Full Text Sources